BioLineRx (BLRX) FCF Margin (2024 - 2026)
BioLineRx (BLRX) posted quarterly FCF Margin of 1649.48% for Q4 2025, down 157615.0% year-over-year from N/an in Q4 2024, and down 234.44% quarter-over-quarter from 493.21% in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) FCF Margin (2024 - 2026) Analysis & Trends
BioLineRx's FCF Margin history runs 2 years deep, the most recent figure standing at 1649.48% for Q4 2025.
- In Q4 2025, FCF Margin fell 157615.0% year-over-year to 1649.48%; the TTM figure through Dec 2025 stood at 684.24% (down 53282.0% YoY), while the FY2025 annual figure was 682.12%, down 53070.0% from the prior year.
- FCF Margin for Q4 2025 stood at 1649.48%, down from 493.21% in the prior quarter.
- The five-year high for FCF Margin was 58.22% in Q2 2025, with the low at 1649.48% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | BioLineRx | 6.64 Bn | 6.64 Bn | 235,000.00 | -1,094.22% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,094.22% |
| Mar 31, 2026 | -476.73% |
| Dec 31, 2025 | -1,649.48% |
| Sep 30, 2025 | -493.21% |
| Jun 30, 2025 | -58.22% |
| Mar 31, 2025 | -1,016.08% |
| Dec 31, 2024 | -73.33% |
| Sep 30, 2024 | -198.77% |
| Jun 30, 2024 | -209.57% |
| Mar 31, 2024 | -205.35% |